A new investment to strengthen production capacity in the United States and support the Group’s international growth
North Brunswick, New Jersey – October 1, 2026 – Biofarma Group today inaugurated its new production facility at 2 King Arthur, located in North Brunswick, New Jersey, further consolidating its industrial presence in the United States. Spanning approximately 16,000 square meters, the new site has been established to complement the existing US Pharma Lab (USPL) facility operating in the same area. It is part of the Group’s international development strategy, aimed at strengthening its production capabilities and providing customers with increasingly comprehensive and flexible solutions.
US Pharma Lab, which joined Biofarma Group in 2023, represents the Group’s North American hub and has extensive expertise in the development and manufacturing of dietary supplements. Its capabilities range from various solid dosage forms to packaging solutions and advanced formulation technologies, across a broad range of dietary supplement formats.
The opening of 2 King Arthur further expands this industrial platform and strengthens the capabilities of the Group’s US facilities to support broad-based growth across the market, responding to evolving demand and the development needs of new products.
“We are proud to celebrate the opening of this new production facility. This is a concrete investment in our ability to respond to market needs, enabling us to serve a broad range of customers even more effectively, with greater flexibility and expertise” - commented Richard White, CEO of USPL – But this achievement is particularly significant because it is the result of the work of the people who have turned a project into reality. Today, we are opening a new chapter in the growth of USPL and our Group, building on the solid foundations we have established and looking to the future with confidence.”
For Alberto Urli, CEO of Biofarma Group, this milestone represents a further step in the Group’s international growth strategy: - “The inauguration of 2 King Arthur marks another step forward in the international development of our Group. Investing in the growth of our production footprint in the United States means being well positioned to respond to evolving market needs through an industrial structure capable of combining expertise, flexibility, and development capabilities. This investment strengthens USPL while also reinforcing Biofarma Group’s global platform, reaffirming our commitment to continued growth through the development of our people, technologies, and production capabilities.”
This continued investment in North Brunswick is expected to create employment opportunities, support local business activity, and strengthen US Pharma Lab’s longstanding connection to the community. The company is proud to continue growing alongside North Brunswick and to play a role in its ongoing economic development.
The inauguration of 2 King Arthur is therefore a tangible expression of the direction in which Biofarma Group is moving: an increasingly international path shaped by investments, expertise, and new opportunities, with a focus on a future that the Group continues to build, day after day.
